ClinicalTrials.gg
RecruitingNCT06905197Updated Oct 23, 2026

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

A Phase 1 interventional study of DZD6008 and Sunvozertinib in Non Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Dizal Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 23, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals — 6 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Dizal Pharmaceuticals.

Planned enrollment
7th of 12
140 · median 160
Started
2025
with 3 others
Phase 1
3 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 1, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Non-Small-Cell Lung by Dizal Pharmaceuticals, or all of them as a file.
02

Study summary

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Read the detailed description

The study includes two parts: Part A (dose escalation) and Part B (dose expansion). In Part A, locally advanced or metastatic NSCLC patients with EGFR mutations following at least 1 prior EGFR TKI regimen will be enrolled. In Part B, locally advanced or metastatic NSCLC patients with EGFR sensitizing mutations, who are previously treated with 1 line of third-generation of EGFR TKI treatment as well as treatment naïve will be enrolled.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be able to provide documented .
  2. Aged ≥ 18 years.
  3. or cytologically confirmed diagnosis of NSCLC, locally advanced or , not suitable for curative therapy.
  4. Documentation of EGFR mutations from a local CLIA-certified laboratory (or equivalent). For Part A monotherapy cohorts and all cohorts of Part B, EGFR sensitizing mutations (Exon19del and/or L858R) are required.
  5. Provide adequate amount of pretreatment tumor samples collected after disease progression on the last EGFR TKI treatment. (previously treated patients) or before study treatment (treatment naïve patients).
  6. Part A: Failed (progressed or are intolerant) from at least 1 prior EGFR TKI regimen. Cohort A of Part B: Failed 1 prior third-generation EGFR TKI regimen. Cohorts B of Part B: Patients who are treatment naïve.
  7. 0 or 1 with predicted ≥ 12 weeks.
  8. Patients with must have a stable BM status.
  9. per 1.1.
  10. Adequate hematopoietic and other organ system functions.
  11. Male Patients with female partners of should use barrier and refrain from donating sperm during their participation in this study and for 3 months following the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Carry other EGFR alterations than T790M and C797X, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions mutations, etc.)(Part B).
  2. NSCLC with mixed small cell lung cancer (SCLC) or NSCLC with histologic SCLC transformation.
  3. Prior treatment with any of the following: 1)Immunotherapy or other antibody therapy within 4 weeks prior to the first administration; 2)Any cytotoxic chemotherapy, drugs or other anticancer drugs from a previous treatment regimen or clinical study within 14 days prior to the first administration; 3)Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose, radiation to more than 30% of the bone marrow or with a wide field of radiation within 28 days before screening; 4)Currently receiving or unable to stop drug or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP)3A4. A of at least 2 weeks for strong inhibitors and 3 weeks for strong inducers is required prior to the first study drug administration; 5)currently receiving or unable to stop drugs known to be sensitive substrate with a narrow therapeutic index. A washout period of at least 14 days is required prior to the first study drug administration; 6)currently receiving or unable to stop drugs known to be proton pump inhibitors. A washout period of at least 7 days is required prior to the first study drug administration; 7)major surgery within 4 weeks of the first administration of DZD6008 or anticipated during the study period.
  4. Any unresolved toxicities from prior anti-cancer therapy greater than Grade 1.
  5. Spinal cord compression or .
  6. Patients with any other within 2 years of the first administration of study drug.
  7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses as judged by investigator.
  8. Patients with active infection, including but not limited to , , and active infection of COVID-19.
  9. Resting > 470 msec; Any abnormalities in rhythm, conduction or morphology of resting ;Any factors that increase the risk of QTc prolongation.
  10. Past medical history of ILD or active ILD.
  11. Diseases which would preclude adequate absorption of DZD6008.
  12. Received a within 2 weeks before the first administration of DZD6008.
  13. Women who are pregnant or breastfeeding.
  14. to active or inactive of DZD6008 or sunvozertinib.
  15. Involvement in the planning and conduct of the study.
  16. Judgment by the investigator that the patient is unlikely to comply with study procedures
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Experimental: Part A Dose Escalation monotherapy cohorts (20 mg once daily [QD])

    Drug: DZD6008

  • Experimental
    Experimental: Part A Dose Escalation monotherapy cohorts (40 mg QD)

    Drug: DZD6008

  • Experimental
    Experimental: Part A Dose Escalation monotherapy cohorts (60 mg QD)

    Drug: DZD6008

  • Experimental
    Experimental: Part A Dose Escalation monotherapy cohorts (90 mg QD)

    Drug: DZD6008

  • Experimental
    Experimental: Part A Dose Escalation monotherapy cohorts (120 mg QD)

    Drug: DZD6008

  • Experimental
    Experimental: Part A Dose Escalation monotherapy cohorts (150 mg QD)

    Drug: DZD6008

  • Experimental
    Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 1)

    Drug: DZD6008 · Drug: Sunvozertinib

  • Experimental
    Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 2)

    Drug: DZD6008 · Drug: Sunvozertinib

  • Experimental
    Experimental: Part A Dose Escalation Combination cohorts (Combination dose 3)

    Drug: DZD6008 · Drug: Sunvozertinib

  • Experimental
    Experimental: Part B Dose Expansion cohort A1 (selected dose 1)

    Drug: DZD6008

  • Experimental
    Experimental: Experimental: Part B Dose Expansion cohort A2 (selected dose 2)

    Drug: DZD6008

  • Experimental
    Experimental: Experimental: Part B Dose Expansion cohort B1 (selected dose 1)

    Drug: DZD6008

  • Experimental
    Experimental: Experimental: Part B Dose Expansion cohort B2 (selected dose 2)

    Drug: DZD6008

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: To assess safety and tolerability

    Number of participants with Dose-limiting Toxicities (DLTs)

    Time frame: 21 days after the first multiple dose

  2. Part A: To assess safety and tolerability

    Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)

    Time frame: Through the study completion, an average of around 1 year

  3. Part B: To assess anti-tumor activity

    Objective Response Rate (ORR) assessed by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Through the study completion, an average of around 1 year

Secondary outcomes

  1. Part A: To characterize the plasma concentration of DZD6008 following single and multiple oral dose administration

    Total concentrations of DZD6008 in plasma

    Time frame: From first dosing to cycle 7 day 1, each cycle is 21 days

  2. Part A: To characterize the plasma concentration of sunvozertinib and metabolite DZ0753 following single and multiple oral dose administration

    Total concentrations of sunvozertinib and metabolite DZ0753 in plasma (combination cohorts only)

    Time frame: From first dosing to cycle 9 day 1, each cycle is 21 days

  3. Part A: To assess the anti-tumor activity

    ORR assessed by investigators per RECIST version 1.1

    Time frame: Through the study completion, an average of around 1 year

  4. Part A: To assess the anti-tumor activity

    Duration of Response (DoR) assessed by investigators per RECIST version 1.1

    Time frame: Through the study completion, an average of around 1 year

  5. Part A: To assess the anti-tumor activity

    Progression Free Survival (PFS) assessed by investigators per RECIST version 1.1

    Time frame: Through the study completion, an average of around 1 year

  6. Part B: To assess the anti-tumor activity

    DoR assessed by investigators per RECIST version 1.1

    Time frame: Through the study completion, an average of around 1 year

  7. Part B: To assess the anti-tumor activity

    Through the study completion, an average of around 1 year

    Time frame: PFS assessed by investigators per RECIST version 1.1

  8. Part B: Plasma concentration of DZD6008

    Total concentrations of DZD6008 in plasma

    Time frame: Time Frame: From first dosing to cycle 11 day 1, each cycle is 21 days

  9. Part B: To assess safety and tolerability

    Number of participants with AEs/SAEs

    Time frame: Through the study completion, an average of around 1 year

07

Study locations

2 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 28 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartActual
May 13, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: y•••@dizalpharma.com · •••5854→y•••@dizalpharma.com · •••8293. See the current contact
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Contact Study contact changed: y•••@dizalpharma.com · •••5854→y•••@dizalpharma.com · •••8293. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06905197
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
May 13, 2025
Primary completion
Sep 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Yingqi Lin
Contact
yingqi.lin@dizalpharma.com
86-21-61098293

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EGFR Mutant-specific Inhibitor DZD6008

Start the discussion